← Back to patent-cliff list
Lysine-3,4-Methylenedioxymethamphetamine
Tier C — Watch / tradeLysine-3,4-Methylenedioxymethamphetamine
University Hospital Basel
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adrenoceptors
Indications (approved)：Post-traumatic stress disorder
Regional status
US
Phase III
2023-10-06
EU
Phase I
2021-12-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lysine-3,4-Methylenedioxymethamphetamine?
Approved indications include: Post-traumatic stress disorder.
When does the Lysine-3,4-Methylenedioxymethamphetamine patent expire?
No public expiry year is available for Lysine-3,4-Methylenedioxymethamphetamine yet; this page updates once verified.
How do I get a quote for Lysine-3,4-Methylenedioxymethamphetamine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02